Effects of a Transitional Care Program on Depression, Self-Efficacy, and Self-Care in Patients With Heart Failure
Effects of a Transitional Care Program on Depression, Self-Efficacy, and Self-Care in Patients With Heart Failure: A Randomized Controlled Trial
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Heart failure is a chronic condition associated with frequent hospitalizations, poor self-care behaviors, psychological distress, and reduced quality of life. Patients with heart failure often experience depression and inadequate self-management after hospital discharge, which may negatively affect treatment adherence and clinical outcomes.
Transitional care programs have been developed to improve continuity of care and support patients during the transition from hospital to home. Structured transitional care interventions may enhance patients' self-efficacy and self-care abilities while reducing depressive symptoms.
This randomized controlled trial aims to evaluate the effects of a structured transitional care program on depression, self-efficacy, and self-care behaviors in patients with heart failure. Eligible participants will be randomly assigned to either the intervention group or the usual care group. The intervention group will receive a structured transitional care program in addition to usual care, whereas the control group will receive usual care only.
Outcomes including depression, self-efficacy, and self-care behaviors will be measured before discharge and at 1 and 3 months after discharge using validated assessment instruments.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Taoyuan City
-
Guishan, Taoyuan City, Taiwan, 33305
- Chang Gung Memorial Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
Patients with a diagnosis of heart failure confirmed by a specialist physician. Patients with heart failure with reduced ejection fraction (HFrEF) and left ventricular ejection fraction (LVEF) ≤40%.
Age ≥20 years. Clear consciousness and no cognitive impairment. Ability to communicate in Mandarin, Taiwanese, or Hakka. Ability to complete the questionnaire independently or with assistance from the researcher.
Exclusion Criteria:
Patients who are unable to be discharged during the current hospitalization. Severe consciousness impairment, cognitive impairment, or severe mental illness affecting study participation.
Patients who are illiterate or unable to express themselves verbally. Patients who are bedridden long-term or unable to perform self-care activities. Patients who refuse to participate in the study. Patients who are already enrolled in a case management program.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Transitional Care Program Group
Participants received a structured transitional care program including discharge education, telephone follow-up, and home care support for 3 months after discharge.
|
A structured transitional care program including discharge education, telephone follow-up, and home care support for 3 months after discharge.
|
|
Aktiv komparator: Usual Care Group
Participants received routine discharge education and standard follow-up care provided by the hospital after dischar
|
Participants received standard discharge routine care provided by the hospital after discharge.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Depression Score Measured by the Patient Health Questionnaire-9 (PHQ-9)
Tidsramme: Baseline (before discharge), 1 month after discharge, and 3 months after discharge.
|
Depression will be assessed using the Patient Health Questionnaire-9 (PHQ-9).
|
Baseline (before discharge), 1 month after discharge, and 3 months after discharge.
|
|
Change in Self-Efficacy Score Measured by the General Self-Efficacy Scale (GSES)
Tidsramme: Baseline (before discharge), 1 month after discharge, and 3 months after discharge.
|
Self-efficacy will be assessed using the General Self-Efficacy Scale (GSES).
|
Baseline (before discharge), 1 month after discharge, and 3 months after discharge.
|
|
Change in Self-Care Behavior Score Measured by the Self-Care of Heart Failure Index (SCHFI)
Tidsramme: Baseline (before discharge), 1 month after discharge, and 3 months after discharge.
|
Self-care behaviors will be assessed using the Self-Care of Heart Failure Index (SCHFI).
|
Baseline (before discharge), 1 month after discharge, and 3 months after discharge.
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 202300968B0
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Overgangspleie
-
Seattle Children's HospitalHar ikke rekruttert ennåCAR T CELL | CAR T Cell TherapyForente stater
-
General Hospital Sveti DuhHar ikke rekruttert ennåBlærekreftcelle Transitional
-
The Affiliated Hospital of Xuzhou Medical UniversityRekrutteringCLL | SLL | CAR-T celleterapiKina
-
Tongji HospitalHebei Taihe Chunyu Biotechnology Co., LtdHar ikke rekruttert ennåCAR-T | Myeloide maligniteterKina
-
Duke UniversityNational Institutes of Health (NIH)RekrutteringHematopoetisk stamcelletransplantasjon | CAR-T celleterapiForente stater
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRekrutteringCAR-T terapikomplikasjonerItalia
-
University Health Network, TorontoRekruttering
-
The Lymphoma Academic Research OrganisationBristol-Myers Squibb; Novartis; Gilead SciencesRekrutteringHematopatologi Kvalifisert eller CAR-t-cellebehandlingFrankrike
-
Xuzhou Medical UniversityHar ikke rekruttert ennåIkke-invasiv overvåking av CAR-T-celler | BCMA-målsatt PET-bildeforming | Biodistribusjon og persistens av CAR-T-celler | GMP-samsvarende tilberedning av radiofarmasøytika
-
Henan Cancer HospitalFundamenta Therapeutics, Ltd.Har ikke rekruttert ennåAllogen, CAR-T, proteinsekvestrering, ikke-genredigertKina
Kliniske studier på Structured Transitional Care Program
-
Chulalongkorn UniversityQueen Sirikit National Institute of Child Health (QSNICH), ThailandFullførtSunn | PreTerm nyfødt | Neonatal intensivavdelingThailand
-
University Health Network, TorontoRekrutteringKronisk smerte | Postoperativ smerte | Opioidavhengighet | OpioidbrukCanada
-
University of Maryland, BaltimoreUniversity of Maryland Medical SystemTilbaketrukketHjertefeil | Lungebetennelse | Hypertensjon | Lungesykdom, kronisk obstruktiv | Gjeninnleggelse av pasient | Diabetes mellitus dårlig kontrollForente stater
-
Peking UniversityCARsgen Therapeutics Co., Ltd.FullførtAvansert solid svulstKina
-
National Cancer Institute (NCI)RekrutteringAkutt lymfatisk leukemi | Lymfoblastisk lymfom | Leukemi, lymfatisk, kronisk, B-celle | Lite lymfatisk lymfom | Leukemi, akutt lymfatisk | B-celle kronisk lymfatisk leukemi | B-lymfocytisk leukemi, kroniskForente stater
-
Mehrdad Abedi, MDNational Cancer Institute (NCI)RekrutteringTilbakevendende diffust stort B-celle lymfom | Refraktært diffust stort B-celle lymfomForente stater